IP Library › Assignment 047207/0254
Patent Assignment
Reel/Frame 047207/0254

Release of Security Interest

Recorded: 2018-10-09 Pages: 15
Assignor
MIDCAP FUNDING V TRUST
Executed: 2017-01-06
Assignee
ACERUS PHARMACEUTICALS SRL
DURANTS BUSINESS CENTRE, SUITE B, DURANTS, CHRIST CHURCH, BB17097, BARBADOS
Covered Properties (52)
Inhaler
Patent: 5,797,392 →
Application: 08/785,960 →
Method for Nasally Administering Aerosols of Therapeutic Agents to Enhance Penetration of the Blood Brain Barrier
Patent: 5,756,071 →
Application: 08/791,549 →
Method and Device for Introducing a Powdered or Particulate Substance into a Person's Nostril
Patent: 6,648,848 →
Application: 09/424,085 →
Method for Introducing a Powdered Substance into a Nostril
Patent: 6,811,543 →
Application: 10/142,688 →
Publication: US 2002/0165482
Inhaler
Patent: 7,661,425 →
Application: 10/595,445 →
Publication: US 2008/0190423
Controlled release delivery system for nasal applications
Application: 10/772,964 →
Publication: US 2005/0100564
Controlled Release Delivery System for Nasal Applications and Method of Treatment
Application: 11/560,187 →
Publication: US 2007/0149454
Controlled Release Delivery System for Nasal Application of Neurotransmitters
Application: 12/418,917 →
Publication: US 2009/0227550
Controlled Release Delivery System for Nasal Applications and Methods of Treatment
Application: 12/796,165 →
Publication: US 2010/0311707
Use of a Container of an Inorganic Additive Containing Plastic Material
Application: 13/152,882 →
Publication: US 2011/0237562
Use of a Container of an Inorganic Additive Containing Plastic Material
Application: 13/194,663 →
Publication: US 2012/0005987
Controlled Release Delivery System for Nasal Applications and Method of Treatment
Patent: 8,784,882 →
Application: 13/194,853 →
Publication: US 2012/0058176
Controlled Release Delivery System for Nasal Application of Neurotransmitters
Patent: 9,186,320 →
Application: 13/194,926 →
Publication: US 2012/0009249
Controlled Release Delivery System for Nasal Applications
Patent: 8,574,622 →
Application: 13/194,928 →
Publication: US 2012/0009250
Controlled Release Delivery System for Nasal Applications
Patent: 8,877,230 →
Application: 13/316,494 →
Publication: US 2012/0083480
Intranasal Methods of Treating Women for Anorgasmia with 0.6% and 0.72% Testosterone Gels
Patent: 9,757,388 →
Application: 13/471,445 →
Publication: US 2013/0059827
Intranasal 0.45% and 0.48% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 13/471,449 →
Publication: US 2013/0040922
Intranasal 0.15% and 0.24% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 13/471,450 →
Publication: US 2013/0045958
Intranasal Lower Dosage Strength Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 13/471,452 →
Publication: US 2013/0040923
Controlled Release Delivery System for Nasal Applications and Methods of Treatment
Patent: 8,784,869 →
Application: 13/547,774 →
Publication: US 2012/0277202
Use of a Container of an Inorganic Additive Containing Plastic Material
Patent: 8,609,043 →
Application: 13/567,878 →
Publication: US 2012/0297730
Controlled Release Topical Testosterone Formulations and Methods
Application: 14/080,695 →
Controlled Release Delivery System for Nasal Applications and Method of Treatment
Patent: 9,238,072 →
Application: 14/322,319 →
Publication: US 2015/0005271
Intranasal 0.6% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/486,251 →
Intranasal 0.45% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/486,252 →
Intranasal 0.15% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/486,254 →
Intranasal Lower Dosage Strength Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/486,266 →
Intranasal 0.45% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/513,495 →
Intranasal 0.6% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/513,497 →
Intranasal 0.15% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/513,499 →
Intranasal 0.15% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
Application: 61/518,903 →
Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
Application: 61/518,913 →
Intranasal 0.45% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
Application: 61/518,916 →
Intranasal 0.6% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
Application: 61/518,921 →
Intranasal 0.6% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/598,329 →
Intranasal 0.45% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/598,333 →
Intranasal 0.15% Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/598,335 →
Intranasal Lower Dosage Strength Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/598,336 →
Controlled Release Topical Testosterone Formulations and Methods
Application: 61/726,564 →
Female Intranasal Lower Dosage Strength Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/726,570 →
Female Intranasal Lower Dosage Strength Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/727,112 →
Male Testosterone Titration Methods, Male Intranasal Testosterone Bio-Adhesive Gel Formulations and Use Thereof for Treating Hypogonadism and Trt
Application: 61/729,138 →
Controlled Release Topical Testosterone Formulations and Methods
Application: 61/729,304 →
Female Intranasal Lower Dosage Strength Testosterone Gel Formulations and Use Thereof for Treating Anorgasmia or Hypoactive Sexual Desire Disorder
Application: 61/729,324 →
Male Testosterone Titration Methods, Male Intranasal Testosterone Bio-Adhesive Gel Formulations and Use Thereof for Treating Hypogonadism and Trt
Application: 61/729,406 →
Methods of Treating Hypogonadism with Tranasal Testosterone Bio-Adhesive Gel Formulations in Male with Allergic Rhinitis, and Methods for Preventing an Allergic Rhinitis Events
Application: 61/802,297 →
One- and Two-Point Titration Methods to Determine Daily Treatment Regimens to Treat Hypogonadism or Male Testosterone Deficiency with an Intranasal Testosterone Bio-Adhesive Gel
Application: 61/802,354 →
Primary and Secondary Efficacy and Safety Endpoints for Controlled Release Topical Testosterone Gel Formulations and Methods
Application: 61/802,388 →
One- and Two-Point Titration Methods to Determine Daily Treatment Regimens to Treat Hypogonadism or Male Testosterone Deficiency with an Intranasal Testosterone Bio-Adhesive Gel
Application: 61/802,724 →
One- and Two-Point Titration Methods to Determine Daily Treatment Regimens to Treat Hypogonadism or Male Testosterone Deficiency with an Intranasal Testosterone Bio-Adhesive Gel
Application: 61/802,727 →
Primary and Secondary Efficacy and Safety Endpoints for Controlled Release Topical Testosterone Gel Formulations and Methods
Application: 61/802,737 →
Primary and Secondary Efficacy and Safety Endpoints for Controlled Release Topical Testosterone Gel Formulations and Methods
Application: 61/802,739 →
Related Assignments (22)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest May 21, 2009
From: MATTERN, CLAUDIA
To: M&P PATENT AKTIENGESELLSCHAFT
Reel/Frame 022721/0553 →
Change of Name Jul 11, 2012
From: DIRECT-HALER A/S
To: KELDMANN HEALTHCARE A/S
Reel/Frame 028546/0363 →
Assignment of Assignor's Interest Jul 11, 2012
From: KELDMANN HEALTHCARE A/S
To: TRIMEL BIOPHARMA SRL
Reel/Frame 028531/0161 →
Assignment of Assignor's Interest Jul 16, 2012
From: KREPPNER, WAYNE; FOGARTY, SIOBHAN; OBEREGGER, WERNER; MAES, PAUL
To: TRIMEL BIOPHARMA SRL
Reel/Frame 028559/0484 →
Assignment of Assignor's Interest Jul 16, 2012
From: KREPPNER, WAYNE; FOGARTY, SIOBHAN; OBEREGGER, WERNER; MAES, PAUL
To: TRIMEL BIOPHARMA SRL
Reel/Frame 028558/0907 →
Assignment of Assignor's Interest Jul 16, 2012
From: KREPPNER, WAYNE; FOGARTY, SIOBHAN; OBEREGGER, WERNER; MAES, PAUL
To: TRIMEL BIOPHARMA SRL
Reel/Frame 028558/0265 →
Assignment of Assignor's Interest Jul 16, 2012
From: KREPPNER, WAYNE; FOGARTY, SIOBHAN; OBEREGGER, WERNER; MAES, PAUL
To: TRIMEL BIOPHARMA SRL
Reel/Frame 028559/0674 →
Security Agreement Jul 19, 2012
From: TRIMEL BIOPHARMA SRL
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 028597/0285 →
Assignment of Assignor's Interest Jul 23, 2012
From: KELDMANN, ERIK; KELDMANN, TROELS; QUESADA, JORGE MARTINEZ; PELAEZ, RICARDO PALACIOS
To: DIRECT-HALER A/S
Reel/Frame 028615/0711 →
Security Agreement Jul 23, 2012
From: TRIMEL BIOPHARMA SRL
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 028613/0855 →
Merger Feb 25, 2014
From: M & P PATNT AKTIENGESELLSCHAFT
To: MATTERN PHARMA AG
Reel/Frame 032291/0349 →
Corrective Assignment to Correct the to Correct the Assignor from M & P Patnt Aktiengesellschaft to M & P Patent Aktiengesellschaft Previously Recorded on Reel 032291 Frame 0349. Assignor(S) Hereby Confirms the Merger Effective 02/04/2014. Mar 10, 2014
From: M & P PATENT AKTIENGESELLSCHAFT
To: MATTERN PHARMA AG
Reel/Frame 032422/0169 →
Release of Security Interest Jul 25, 2014
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: TRIMEL BIOPHARMA SRL
Reel/Frame 033417/0304 →
Security Interest Jul 25, 2014
From: TRIMEL BIOPHARMA SRL
To: MIDCAP FUNDING V, LLC
Reel/Frame 033416/0897 →
Release of Security Interest Jul 25, 2014
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: TRIMEL BIOPHARMA SRL
Reel/Frame 033417/0094 →
Change of Name Sep 23, 2015
From: TRIMEL BIOPHARMA SRL
To: ACERUS PHARMACEUTICAL SRL
Reel/Frame 036667/0608 →
Corrective Assignment to Correct the Name of the Assignee Previously Recorded on Reel 036667 Frame 0608. Assignor(S) Hereby Confirms the Assignment. Oct 7, 2015
From: TRIMEL BIOPHARMA SRL
To: ACERUS PHARMACEUTICALS SRL
Reel/Frame 036807/0886 →
Assignment of Assignor's Interest Oct 9, 2015
From: TRIMEL BIOPHARMA SRL; TRIMEL PHARMACEUTICALS CORP.
To: ACERUS PHARMACEUTICALS SRL
Reel/Frame 036827/0897 →
Assignment of Assignor's Interest Mar 20, 2017
From: MATTERN PHARMA AG
To: M ET P PHARMA AG
Reel/Frame 041645/0897 →
Change of Name Dec 20, 2017
From: ACERUS PHARMACEUTICALS SRL
To: ACERUS BIOPHARMA INC.
Reel/Frame 044958/0562 →
Assignment of Assignor's Interest Dec 19, 2019
From: TRIMEL BIOPHARMA SRL
To: ACERUS PHARMACEUTICALS SRL
Reel/Frame 051337/0832 →
Assignment of Assignor's Interest Apr 12, 2023
From: PHAGELUX (CANADA), INC.
To: PRECISIOBIOTIX TECHNOLOGIES INC.
Reel/Frame 063307/0577 →